Investigational drug · Phase 2
ABX-002
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Major Depressive Disorder, Bipolar Disorder Depression.
Phase 2Last checked: Nov 19, 2026Latest source record: May 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "ABX-002"
First trial start
2024
Sep 20, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABX-002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder
- Bipolar Disorder Depression
Approved drugs for the same conditions: Depression (major depressive disorder) · Bipolar disorder · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ABX-002" as an intervention, largest first.
- Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)Pivotal-lookingRecruiting
Autobahn Therapeutics, Inc.Industry
NCT06633016 · 230 participants (planned) · Start Sep 20, 2024 · Primary completion Jun 2026
Drug: ABX-002 · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 50 sites in all
Autobahn Therapeutics, Inc.Industry
NCT05528315 · 48 participants · Start Oct 12, 2022 · Primary completion Jun 26, 2023
Drug: ABX-002; Placebo · For: MDD
Sites: Melbourne, Australia
- Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in AdultsActive, not recruiting
Autobahn Therapeutics, Inc.Industry
NCT06869187 · 35 participants (planned) · Start Mar 28, 2025 · Primary completion Apr 22, 2026
Drug: ABX-002 · For: Bipolar Disorder Depression
Sites: Walnut Creek, California; Cromwell, Connecticut; Hartford, Connecticut · 14 sites in all
Autobahn Therapeutics, Inc.Industry
NCT07652697 · 18 participants · Start Jan 2, 2025 · Primary completion Feb 17, 2025
Drug: ABX-002 · For: Healthy
Sites: Lincoln, Nebraska
Newest research
PubMed records naming it or its code names, newest first.
- Liquid Compared to Solid Oral Formulations of the Thyroid Hormone Receptor Agonist Elunetirom Under Fasted and Fed Conditions in Healthy Participants.
Harris JR, van Haarst AD, Baccei J, et al. · Clin Transl Sci 2026
Also in development for Major Depressive Disorder
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- BHV-7000Phase 36 trials
Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder
- NBI-1065845TAK-653, OsavampatorPhase 35 trials
Neurocrine Biosciences · Major Depressive Disorder
- CYM-53093Navacaprant, NMRA-335140Phase 34 trials
Neumora Therapeutics, Inc. · Major Depressive Disorder, Major Depressive Episode Associated With Bipolar II Disorder
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- PsilocybinCOMP360Phase 34 trials
COMPASS Pathways · Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.